- Home
- SNGX vs CYCN Comparison
SNGX vs CYCN Comparison
Compare SNGX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- CYCN
- Stock Information
- Founded
- SNGX 1987
- CYCN 2018
- Country
- SNGX United States
- CYCN United States
- Employees
- SNGX N/A
- CYCN N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- CYCN Health Care
- Exchange
- SNGX Nasdaq
- CYCN Nasdaq
- Market Cap
- SNGX 10.1M
- CYCN 8.0M
- IPO Year
- SNGX 1987
- CYCN N/A
- Fundamental
- Price
- SNGX $2.79
- CYCN $2.45
- Analyst Decision
- SNGX Strong Buy
- CYCN
- Analyst Count
- SNGX 1
- CYCN 0
- Target Price
- SNGX $6.00
- CYCN N/A
- AVG Volume (30 Days)
- SNGX 871.1K
- CYCN 25.2K
- Earning Date
- SNGX 11-07-2025
- CYCN 11-13-2025
- Dividend Yield
- SNGX N/A
- CYCN N/A
- EPS Growth
- SNGX N/A
- CYCN N/A
- EPS
- SNGX N/A
- CYCN N/A
- Revenue
- SNGX N/A
- CYCN $2,174,000.00
- Revenue This Year
- SNGX N/A
- CYCN N/A
- Revenue Next Year
- SNGX N/A
- CYCN N/A
- P/E Ratio
- SNGX N/A
- CYCN N/A
- Revenue Growth
- SNGX N/A
- CYCN N/A
- 52 Week Low
- SNGX $1.09
- CYCN $1.27
- 52 Week High
- SNGX $6.23
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- SNGX 49.04
- CYCN 48.35
- Support Level
- SNGX $2.58
- CYCN $2.13
- Resistance Level
- SNGX $2.98
- CYCN $2.62
- Average True Range (ATR)
- SNGX 0.20
- CYCN 0.23
- MACD
- SNGX -0.08
- CYCN 0.02
- Stochastic Oscillator
- SNGX 32.81
- CYCN 42.13
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.